Insmed Incorporated detracted from the Alger Mid Cap Focus Fund's performance in the second quarter of 2026, even though its headline results were generally better than expected. The fund noted that investors focused on early launch dynamics for Brinsupri, with concerns about patient additions, discontinuation rates, and compliance trends raising questions about the quality and durability of the launch. Insmed is a commercial-stage biopharmaceutical company with an approved portfolio that includes Brinsupri and Arikayce, and its opportunity is tied to expanding adoption of these products while advancing a pipeline for areas of unmet medical need. The stock closed at $108.32 per share on July 17, 2026, with a market capitalization of $23.49 billion, and posted a one-month return of 9.85% and a 52-week gain of 5.39%. Management has begun providing greater detail around launch dynamics, and the fund believes improved execution and additional data could help restore investor confidence over time.
Insmed IncInvestors concerned about early launch dynamics for Brinsupri, including patient additions, discontinuation rates, and compliance trends, questioning launch quality and durability.